Publications

Pandey S, Singh A, Yang G, d'Andrea FB, Jiang X, Hartman TE, Mosior JW, Bourland R, Gold B, Roberts J et al..  2021.  Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis.. Microbiol Spectr. 9(2):e0092821.

McElvaine AT, Hawkins-Salsbury JA, Arora VM, Gladwin MT, Goldenring JR, Huston DP, Krakow D, Rhee K, Solway J, Steinman RA et al..  2021.  Innovations in MD-only physician-scientist training: experiences from the Burroughs Wellcome Fund physician-scientist institutional award initiative.. J Clin Invest. 131(10)

Planck KA, Rhee K.  2021.  Metabolomics of Mycobacterium tuberculosis.. Methods Mol Biol. 2314:579-593.

Schrader SM, Botella H, Jansen R, Ehrt, Sabine, Rhee K, Nathan C, Vaubourgeix J.  2021.  Multiform antimicrobial resistance from a metabolic mutation.. Sci Adv. 7(35)

Szeri F, Lundkvist S, Donnelly S, Engelke UFH, Rhee K, Williams CJ, Sundberg JP, Wevers RA, Tomlinson RE, Jansen RS et al..  2020.  The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP.. PLoS Genet. 16(7):e1008884.

Whitaker M, Ruecker N, Hartman T, Klevorn T, Andres J, Kim J, Rhee K, Ehrt, Sabine.  2020.  Two interacting ATPases protect Mycobacterium tuberculosis from glycerol and nitric oxide toxicity.. J Bacteriol.

Daou N, Wang Y, Levdikov VM, Nandakumar M, Livny J, Bouillaut L, Blagova E, Zhang K, Belitsky BR, Rhee K et al..  2019.  Impact of CodY protein on metabolism, sporulation and virulence in Clostridioides difficile ribotype 027.. PLoS One. 14(1):e0206896.

Lu X, Williams Z, Hards K, Tang J, Cheung C-Y, Aung HLin, Wang B, Liu Z, Hu X, Lenaerts A et al..  2019.  Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.. ACS Infect Dis. 5(2):239-249.

Tiwari D, Park SWoong, Essawy MM, Dawadi S, Mason A, Nandakumar M, Zimmerman M, Mina M, Ho HPin, Engelhart CA et al..  2018.  Targeting protein biotinylation enhances tuberculosis chemotherapy.. Sci Transl Med. 10(438)

Lazar N, Fay A, Nandakumar M, Boyle KE, Xavier J, Rhee K, Glickman MS.  2017.  Control of biotin biosynthesis in mycobacteria by a pyruvate carboxylase dependent metabolic signal.. Mol Microbiol. 106(6):1018-1031.

Park Y, Pacitto A, Bayliss T, Cleghorn LAT, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M et al..  2017.  Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.. ACS Infect Dis. 3(1):18-33.

Boyle KE, Monaco HT, Deforet M, Yan J, Wang Z, Rhee K, Xavier JB.  2017.  Metabolism and the Evolution of Social Behavior.. Mol Biol Evol. 34(9):2367-2379.

Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH, Reddy VP, Chinta KC, Mazorodze JH, Glasgow JN, Richard-Greenblatt M et al..  2016.  Ergothioneine Maintains Redox and Bioenergetic Homeostasis Essential for Drug Susceptibility and Virulence of Mycobacterium tuberculosis.. Cell Rep. 14(3):572-585.

Maksymiuk C, Ioerger T, Balakrishnan A, Bryk R, Rhee K, Sacchettini J, Nathan C.  2015.  Comparison of transposon and deletion mutants in Mycobacterium tuberculosis: The case of rv1248c, encoding 2-hydroxy-3-oxoadipate synthase.. Tuberculosis (Edinb). 95(6):689-694.

Nandakumar M, Prosser GA, de Carvalho LPedro S, Rhee K.  2015.  Metabolomics of Mycobacterium tuberculosis.. Methods Mol Biol. 1285:105-15.

Ehrt, Sabine, Rhee K, Schnappinger D.  2015.  Mycobacterial genes essential for the pathogen's survival in the host.. Immunol Rev. 264(1):319-26.

Ganapathy U, Marrero J, Calhoun S, Eoh H, de Carvalho LPedro Sori, Rhee K, Ehrt, Sabine.  2015.  Two enzymes with redundant fructose bisphosphatase activity sustain gluconeogenesis and virulence in Mycobacterium tuberculosis.. Nat Commun. 6:7912.

Puckett S, Trujillo C, Eoh H, Marrero J, Spencer J, Jackson M, Schnappinger D, Rhee K, Ehrt, Sabine.  2014.  Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis.. PLoS Pathog. 10(5):e1004144.

Patel SJ, Oliveira AP, Zhou JJulia, Alba L, E Furuya Y, Weisenberg SA, Jia H, Clock SA, Kubin CJ, Jenkins SG et al..  2014.  Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.. Am J Infect Control. 42(6):626-31.

Zhou JJulia, Patel SJ, Jia H, Weisenberg SA, E Furuya Y, Kubin CJ, Alba L, Rhee K, Saiman L.  2013.  Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units.. Infect Control Hosp Epidemiol. 34(3):274-83.

Rhee K.  2013.  Minding the gaps: metabolomics mends functional genomics.. EMBO Rep. 14(11):949-50.

Ehrt, Sabine, Rhee K.  2013.  Mycobacterium tuberculosis metabolism and host interaction: mysteries and paradoxes.. Curr Top Microbiol Immunol. 374:163-88.

Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, Ehrt, Sabine, Nathan C.  2011.  Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes.. Cell Host Microbe. 9(1):21-31.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WYee, Patel V, Beer D, Walker JR, Duraiswamy J et al..  2010.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.. Nat Commun. 1:57.

Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S et al..  2008.  Selective killing of nonreplicating mycobacteria.. Cell Host Microbe. 3(3):137-45.